1
|
Rimini M, Casadei-Gardini A, Brandi G, Leone F, Fornaro L, Pella N, Silvestris N, Montagnani F, Lonardi S, Lai E, Galizia E, Santini D, Palloni A, Filippi R, Masi G, Aprile G, Aglietta M, Frega G, Fenocchio E, Vivaldi C, Satolli MA, Salani F, Scartozzi M, Faloppi L, Pellino A, Sperti E, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Cucchetti A. Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. J Chemother 2022; 34:543-549. [PMID: 35156913 DOI: 10.1080/1120009x.2022.2036557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Biliary tract cancer's (BTC) treatment main stone for advanced stages is constituted by chemotherapy. Surgical centralization and physicians' confidence in the use of new technologies and molecular analysis turned out to be of interest and potentially influencing survival. After applying a random-effect model, the relationship between each clinical variable on the main outcome was investigated through multilevel mixed-effects logistic regression. The risk-standardized outcomes were calculated for each centre involved. In the unadjusted cohort the median survival was 8.6 months (95%C.I.: 7.8-9.3) with a 9-month survival rate of 48.3% (95%C.I.: 45.0-51.5). A substantial heterogeneity across hospitals was found (I2: 70.3%). In multilevel mixed effect logistic regression, male, being treated for gallbladder cancer, higher ECOG, increased NLR, CEA and Ca 19.9 and low value of haemoglobin showed to increase the odds for 9-month mortality. The model estimated that the residual variance observed in 9-month mortality was attributable for the 2.6% to the treating hospital. Through a multilevel mixed effect model, average risk-standardized mortality within 9 months was 50.1%. As noticeable, all hospital's risk-standardized mortality falls within 95%C.I., thus all participating centres provided similar outcomes when adjusted for patient case-mix. Heterogenicity between hospital did not affect the outcome in term of overall survival.
Collapse
Affiliation(s)
- Margherita Rimini
- Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy
| | - Andrea Casadei-Gardini
- Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.,Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy
| | - Giovanni Brandi
- Oncology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola-Malpighi Hospital, Bologna, Italy
| | - Francesco Leone
- Division of Medical Oncology, ASL BI, Nuovo Ospedale degli Infermi, Ponderano, BI, Italy
| | - Lorenzo Fornaro
- U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, Italy
| | | | - Nicola Silvestris
- Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.,Department of Oncology, IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, Bari, Italy
| | - Francesco Montagnani
- Division of Medical Oncology, ASL BI, Nuovo Ospedale degli Infermi, Ponderano, BI, Italy
| | - Sara Lonardi
- Oncology Unit 3, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Eleonora Lai
- Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy
| | - Eva Galizia
- Macerata General Hospital, Medical Oncology Unit, Macerata, Italy
| | - Daniele Santini
- Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy
| | - Andrea Palloni
- Oncology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola-Malpighi Hospital, Bologna, Italy
| | - Roberto Filippi
- Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, TO, Italy.,Department of Oncology, University of Turin, Torino, Italy.,Centro Oncologico Ematologico Subalpino, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
| | - Gianluca Masi
- U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, Italy
| | | | - Massimo Aglietta
- Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, TO, Italy.,Department of Oncology, University of Turin, Torino, Italy
| | - Giorgio Frega
- Oncology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola-Malpighi Hospital, Bologna, Italy
| | - Elisabetta Fenocchio
- Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, TO, Italy
| | - Caterina Vivaldi
- U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, Italy
| | - Maria Antonietta Satolli
- Department of Oncology, University of Turin, Torino, Italy.,Centro Oncologico Ematologico Subalpino, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
| | - Francesca Salani
- U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, Italy
| | - Mario Scartozzi
- Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy
| | - Luca Faloppi
- Macerata General Hospital, Medical Oncology Unit, Macerata, Italy
| | - Antonio Pellino
- Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.,Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Elisa Sperti
- Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy
| | - Valentina Burgio
- Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy
| | | | | | - Stefano Cascinu
- Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.,Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy
| | - Alessandro Cucchetti
- Department of Medical and Surgical Sciences, DIMEC, Alma Mater Studiorum, University of Bologna, Bologna, Italy.,Oncology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
| |
Collapse
|
2
|
Faloppi L, Puzzoni M, Gardini AC, Silvestris N, Masi G, Marisi G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M. Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study. Target Oncol 2020; 15:801-802. [PMID: 33170485 DOI: 10.1007/s11523-020-00773-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The listing of the author names and affiliations, which previously read.
Collapse
Affiliation(s)
- Luca Faloppi
- Medical Oncology Unit, Macerata General Hospital, ASUR Marche AV3, Macerata, Italy.,Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
| | - Marco Puzzoni
- Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
| | | | - Nicola Silvestris
- Medical Oncology Unit, IRCCS Giovanni Paolo II Cancer Center, Bari, Italy
| | - Gianluca Masi
- Medical Oncology Unit, University of Pisa, Pisa, Italy
| | | | | | | | - Pina Ziranu
- Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
| | - Maristella Bianconi
- Medical Oncology Unit, San Benedetto del Tronto Hospital, ASUR Marche AV5, San Benedetto del Tronto, Italy
| | - Cristian Loretelli
- International Center for T1D, Department of Biomedical and Clinical Sciences, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi "L. Sacco", University of Milan, Milan, Italy
| | - Laura Demurtas
- Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
| | - Eleonora Lai
- Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
| | | | - Eva Galizia
- Medical Oncology Unit, Macerata General Hospital, ASUR Marche AV3, Macerata, Italy
| | - Paola Ulivi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy
| | - Nicola Battelli
- Medical Oncology Unit, Macerata General Hospital, ASUR Marche AV3, Macerata, Italy
| | | | | | - Mario Scartozzi
- Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy. .,Oncologia Medica, Azienda Ospedaliera Universitaria Cagliari, Presidio Policlinico Universitario "Duilio Casula", Km 4500 Bivio per Sestu, S.S. 554, 09042, Monserrato, CA, Italy.
| |
Collapse
|
3
|
Faloppi L, Puzzoni M, Casadei Gardini A, Silvestris N, Masi G, Marisi G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M. Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Target Oncol 2020; 15:115-126. [DOI: 10.1007/s11523-020-00698-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
4
|
Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Montironi R. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Rev Cardiovasc Ther 2019; 17:917-927. [PMID: 31829045 DOI: 10.1080/14779072.2019.1704626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Objective: Hypertension is a common adverse event with targeted agents in cancer patients and can lead to serious and sometimes lethal cardiovascular complications. The authors performed a meta-analysis of clinical trials aiming to evaluate the incidence and Relative Risk (RR) of developing all-grade and high-grade Hypertension Events (HE) in patients with solid tumors receiving targeted therapy.Methods: A review of citations from PubMed was performed and studies were selected based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The search was limited to randomized phase III trials published in English focused on the efficacy and safety of targeted agents in cancer patients, reporting data on HE. Incidence, RR and relative 95% CIs were analyzed using random or fixed-effects models. Overall incidences were calculated and further compared with the chi-squared test for proportions.Results: Ninety-three phase III trials were included, with a total of 68,077 patients. Prostate cancer was the most represented (18.9%), followed by breast cancer (17.3%) and colorectal cancer (16.4%). The incidence of all- and high-grade HE was 23.47% and 8.57%, respectively, with the highest incidence of serious HE reported by adjuvant Sunitib/Sorafenib (29.03%). The highest RR of high-grade HE was observed with Bevacizumab in patients with advanced cervical cancer. By drug category, the highest RR of high-grade HE was reported by VEGFR/EGFR TKIs.Conclusion: According to these data, monitoring this class of toxicities is of primary importance to avoid hypertension worsening and, thus, the risk of major cardiovascular events.
Collapse
Affiliation(s)
| | - Alessandro Conti
- Azienda Ospedaliera dell'Alto Adige, Bressanone/Brixen Hospital, Bressanone, Italy
| | | | | | - Luca Faloppi
- Oncology Unit, Macerata Hospital, Macerata, Italy
| | - Eva Galizia
- Oncology Unit, Macerata Hospital, Macerata, Italy
| | | | - Francesco Piva
- Department of Specialistic Clinical and Odontostomatological Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Sebastiano Buti
- Division of Oncology, University Hospital of Parma, Parma, Italy
| | - Roberto Iacovelli
- Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Verona, Italy
| | - Benedetta Ferretti
- Oncologia Medica, Ospedale di San Severino, San Severino Marche (MC), Macerata, Italy
| | - Alessia Cimadamore
- Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, Ancona, Italy
| | - Marina Scarpelli
- Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, Ancona, Italy
| | | | - Liang Cheng
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | | | - Rodolfo Montironi
- Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, Ancona, Italy
| |
Collapse
|
5
|
Faloppi L, Nabissi M, Santoni M, Maggi F, Galizia E, Miccini F, Bianconi M, Puzzoni M, Astara G, Battelli N, Santoni G, Scartozzi M. RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e15663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15663 Background: For over ten years the most stimulating results in systemic therapy for advanced HCC derived from the use of sorafenib (S). But in the last two years several drugs, in particular other multikinase inhibitors like lenvatinib (L), regorafenib (R), cabozantinib (C), proved to be effective both as an alternative or a sequential therapy to sorafenib. In this widened and rapidly increased scenario, without any head-to-head trial, clinicians struggle to define the best drug and the best treatment sequence. Aim of the first part of this project is to evaluate the activity of different treatment sequences in HCC cell lines to pave the way to a future clinical trial investigating their efficacy. Methods: Compounds of S, R, L and C were dissolved in DMSO and aliquoted. HepG2 cell line, obtained from ECACC (Salisbury, UK), was seeded at the density of 3 x 104 cells/ml. After 24 h of incubation, compounds or vehicle (DMSO) were added. Treatments were performed in single administration and six replicates were carried out for each dose. At 48h post-treatment, cells were fixed and stained with acid solution. The absorbance was measured at 520 nm using an ELISA reader (BioTek Instruments, USA). The assay was also performed with the sequences of: S-R, S-C, L-R, L-C (first line treatments for 48h followed by the second compound for 48h). Higher doses than the minimum inhibiting one were tested. Results: S showed superior activity than L as first line compound. In the sequence assay S-C and S-R seems to have the best results in terms of cell viability. After L the best compound appears to be R. See table. Conclusions: Our results showed relevant variations in cell viability with different drug sequences. Already planned analyses in the RISE-HEP project in vivo and in humans are mandatory to confirm which sequence would have the highest efficacy.[Table: see text]
Collapse
Affiliation(s)
- Luca Faloppi
- Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy
| | | | - Matteo Santoni
- Medical Oncology Unit, Macerata General Hospital, Macerata, Italy
| | - Federica Maggi
- Dept. of Experimental Madicine, University of Rome La Sapienza, Rome, Italy
| | - Eva Galizia
- Medical Oncology Unit, Macerata General Hospital, Macerata, Italy
| | | | - Maristella Bianconi
- Medical Oncology Unit, Ospedale "Madonna del Soccorso", San Benedetto Del Tronto, Italy
| | - Marco Puzzoni
- Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy
| | - Giorgio Astara
- Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy
| | - Nicola Battelli
- Medical Oncology Unit, Macerata General Hospital, Macerata, Italy
| | | | - Mario Scartozzi
- Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy
| |
Collapse
|
6
|
Orgiano L, Bruder F, Madeddu C, Marconcini R, Gambale E, Galizia E, Stucci S, Spagnolo F, Di Guardo L, Loi C, Dessi A, Massa E, Massa D, Astara G, Del Vecchio M, Silvestris F, De Tursi M, Falcone A, Queirolo P, Scartozzi M. 409P CARAMEL study: ClinicAl prognostic biomarkers for Ipilimumab-Related outcome in metastatic MELanoma patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw589.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Orgiano L, Bruder F, Madeddu C, Marconcini R, Gambale E, Galizia E, Stucci S, Spagnolo F, Di Guardo L, Loi C, Dessi A, Massa E, Massa D, Astara G, Del Vecchio M, Silvestris F, De Tursi M, Falcone A, Queirolo P, Scartozzi M. 409P CARAMEL study: ClinicAl prognostic biomarkers for Ipilimumab-Related outcome in metastatic MELanoma patients. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00567-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
8
|
Orgiano L, Bruder F, Madeddu C, Marconcini R, Gambale E, Galizia E, Stucci S, Spagnolo F, Di Guardo L, Loi C, Pani F, Massa D, Massa E, Astara G, Del Vecchio M, Silvestris F, de tursi M, Falcone A, Queirolo P, Scartozzi M. CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
ORGIANO L, Bruder F, Madeddu C, Marconcini R, Gambale E, Galizia E, Stucci S, Spagnolo F, Di Guardo L, Loi C, Pani F, Massa D, Massa E, Astara G, Del Vecchio M, Silvestris F, De Tursi M, Falcone A, Queirolo P, Scartozzi M. CARAMEL study: ClinicAl prognostic biomarkers for Ipilimumab-Related outcome in metastatic MELanoma patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw341.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Orgiano L, Bruder F, Madeddu C, Marconcini R, Gambale E, Galizia E, Stucci S, Spagnolo F, Di Guardo L, Carla L, Pani F, Massa D, Massa E, Astara G, Del Vecchio M, Silvestris F, Natoli C, Falcone A, Queirolo P, Scartozzi M. CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e21009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Laura Orgiano
- AOU Cagliari, Department of Medical Oncology, Monserrato, Italy
| | - Francesca Bruder
- Businco Hospital, Department of Medical Oncology, Cagliari, Italy
| | - Clelia Madeddu
- AOU Cagliari, Department of Medical Oncology, Cagliari, Italy
| | | | | | - Eva Galizia
- Oncologia Medica, Ospedale Profili, Fabriano, Italy
| | | | | | | | - Loi Carla
- AOU Cagliari, Department of Medical Oncology, Monserrato, Italy
| | - Fabiana Pani
- Endocrinology and Diabetes Unit, Department of Medical SciencesUniversity of Cagliari, Cagliari, Italy
| | - Daniela Massa
- Businco Hospital, Department of Medical Oncology, Cagliari, Italy
| | - Elena Massa
- Department of Medical Oncology, Cagliari, Italy
| | - Giorgio Astara
- AOU Cagliari, Department of Medical Oncology, Cagliari, Italy
| | | | | | - Clara Natoli
- Department of Experimental and Clinical Sciences, University, Chieti, Italy
| | | | | | | |
Collapse
|
11
|
Gubbiotti M, Pistilli B, Tudini M, Benedetti G, Galizia E, Rusiello M, Latini L. Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient. Future Oncol 2015; 11:17-22. [DOI: 10.2217/fon.15.148] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m2 on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood–brain barrier.
Collapse
Affiliation(s)
- Marta Gubbiotti
- Oncology Unit, Macerata Hospital, Area Vasta 3 Marche, Via S. Lucia, 1 - 62100, Macerata, Italy
| | - Barbara Pistilli
- Oncology Unit, Macerata Hospital, Area Vasta 3 Marche, Via S. Lucia, 1 - 62100, Macerata, Italy
| | - Marianna Tudini
- Oncology Unit, Macerata Hospital, Area Vasta 3 Marche, Via S. Lucia, 1 - 62100, Macerata, Italy
| | - Giovanni Benedetti
- Oncology Unit, Macerata Hospital, Area Vasta 3 Marche, Via S. Lucia, 1 - 62100, Macerata, Italy
| | - Eva Galizia
- Oncology Unit, Macerata Hospital, Area Vasta 3 Marche, Via S. Lucia, 1 - 62100, Macerata, Italy
| | - Marco Rusiello
- Ophthalmology Unit, Macerata Hospital, Area Vasta 3 Marche, Via S. Lucia,1 - 62100, Macerata, Italy
| | - Luciano Latini
- Ophthalmology Unit, Macerata Hospital, Area Vasta 3 Marche, Via S. Lucia,1 - 62100, Macerata, Italy
| |
Collapse
|
12
|
Bittoni A, Scartozzi M, Pistelli M, Galizia E, Del Prete M, Giampieri R, Faloppi L, Bianconi M, Maccaroni E, Cascinu S. Intensive up-front treatment versus a sequential approach in advanced gastric cancer patients: Does first-line matter? J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e14663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14663 Background: The definition of the standard chemotherapy regimen for advanced gastric cancer is still a matter of debate. A recent meta-analysis suggested that the addition of a third drug to a doublet regimen should be considered the state-of-the-art strategy to improve overall survival. Aim of our analysis was to retrospectively assess whether an intensive, three-drugs, front line approach could be comparable to a sequential (two-drugs front line then second line) in terms of RR (response rate), PFS (progression free survival) and OS (overall survival) in advanced gastric cancer patients. Methods: Patients with metastatic gastric cancer who have received a first-line combination chemotherapy with a two or three-drugs regimen were included in our analysis. We divided our patients into two groups, A and B, based on the first line chemotherapy administered (group A=three drugs; group B= two drugs). Results: A total of 390 patients were eligible for our analysis. 211 patients (54%) received three chemotherapeutic agents (group A) and 179 patients (46%) received a two drugs regimen as first-line combination chemotherapy (group B). The 2 groups of patients resulted comparable for all known prognostic factors of clinical relevance. RR for group A and B was 46.5% and 28%, respectively (p=0,0007), median PFS was 7.12 months in group A and 3.96 months in group B (p<0,0001). No significantly difference resulted for the median OS of patients in the two groups (13 months for group A and 11.8 months for group B; p= 0.962). Conclusions: The addition of a third drug to a doublet chemotherapy regimen appeared more active in terms of response rate and PFS. However median OS resulted comparable. On this basis, a triplet regimen may represent an optimal choice, particularly when response and PFS are relevant treatment endpoints. Nevertheless the use of a sequential approach may also represent a reasonable strategy for patients unwilling or unable to undergo a more intensive treatment without compromising OS.
Collapse
Affiliation(s)
- Alessandro Bittoni
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy
| | - Mario Scartozzi
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy
| | - Mirco Pistelli
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy
| | - Eva Galizia
- Oncologia Medica, Ospedale Profili, Fabriano, Italy
| | - Michela Del Prete
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy
| | - Riccardo Giampieri
- A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy
| | - Luca Faloppi
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy
| | - Maristella Bianconi
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy
| | - Elena Maccaroni
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy
| | - Stefano Cascinu
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy
| |
Collapse
|
13
|
Maccaroni E, Giampieri R, Scartozzi M, Del Prete M, Faloppi L, Bianconi M, Bittoni A, Galizia E, Loretelli C, Belvederesi L, Cascinu S. Pretreatment levels of serum lactate dehydrogenase (LDH) and clinical outcome in metastatic colorectal cancer patients receiving first-line chemotherapy and bevacizumab. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.4_suppl.514] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
514 Background: No predictive marker for efficacy of a Bevacizumab-based therapy has been identified in metastatic colorectal cancer. Soluble LDH levels seem to be related to increased angiogenesis. The focus of this analysis is whether high levels of LDH can be related to higher benefit of bevacizumab-based therapy in this setting. Methods: Eligible patients were metastatic colorectal cancer patients treated in 1st line setting with a chemotherapy doublet and bevacizumab in the last year. A historical control group was also formed by collecting data of patients treated with only a chemotherapy doublet. Pre-treatment LDH serum levels were collected for all patients. Cut-off level for soluble LDH was determined via ROC curve. Primary end-point was difference in progression free survival between the two groups. Secondary end-points were overall survival and response rates. Results: 82 patients treated with first line containing bevacizumab were eligible for our analysis. 138 patients were identified as control group. The two groups were comparable for major clinical characteristics. LDH cut-off level was stated at 588 mg/dl. In the control group PFS of 4.2 and 8 months were observed for LDH high and low levels (p=0.0003,HR:0.2973,95%CI:0.0318 to 0.3543). OS were 19.6 and 34.9 months (p=0.0014,HR:0.2484,95%CI: 0.0188 to 0.3884). No significant differences were seen for response rates (with 20% vs 39% partial responses, p=0.1671). In the group of patients treated with Bevacizumab, PFS of 8.5 and 7.3 months were observed respectively for LDH high and low levels (p=0.2,HR:0.6360,95%CI:0.2528 to 1.4185). OS were 26.6 and 22 months (p=0.7,HR:0.8480,95%CI:0.2307 to 2.9563). Improved response rate for LDH high patients could be seen (58% vs 14% partial responses, p=0.0243). Conclusions: These data confirm the role of soluble LDH as marker of worse outcome for unselected patients and also suggest a role as potential marker of increased effectiveness of Bevacizumab based therapy.
Collapse
Affiliation(s)
- Elena Maccaroni
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Riccardo Giampieri
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Mario Scartozzi
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Michela Del Prete
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Luca Faloppi
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Maristella Bianconi
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Alessandro Bittoni
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Eva Galizia
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Cristian Loretelli
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Laura Belvederesi
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| | - Stefano Cascinu
- Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Anona, Italy; Scuola di Specializzazione in
| |
Collapse
|
14
|
Bittoni A, Scartozzi M, Pistelli M, Galizia E, Del Prete M, Giampieri R, Faloppi L, Bianconi M, Maccaroni E, Cascinu S. Intensive up-front treatment versus a sequential approach in advanced gastric cancer patients: Does first line matter? J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.4_suppl.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
131 Background: The definition of the standard chemotherapy regimen for advanced gastric cancer is still a matter of debate. A recent meta-analysis suggested that the addition of a third drug to a doublet regimen should be considered the state-of-the-art strategy to improve overall survival. Aim of our analysis was to retrospectively assess whether an intensive, three-drugs, front line approach could be comparable to a sequential (two-drugs front line then second line) in terms of RR (response rate), PFS (progression free survival), and OS (overall survival) in advanced gastric cancer patients. Methods: Patients with metastatic gastric cancer who have received a first-line combination chemotherapy with a two or three-drugs regimen were included in our analysis. We divided our patients into two groups, A and B, based on the first line chemotherapy administered (group A=three drugs; group B= two drugs). Results: A total of 390 patients were eligible for our analysis. 211 patients (54%) received three chemotherapeutic agents (group A) and 179 patients (46%) received a two drugs regimen as first-line combination chemotherapy (group B). The 2 groups of patients resulted comparable for all known prognostic factors of clinical relevance. RR for group A and B was 46,5% and 28%, respectively (p=0,0007), median PFS was 7,12 months in group A and 3,96 months in group B (p<0,0001). No significantly difference resulted for the median OS of patients in the two groups (13 months for group A and 11,8 months for group B; p= 0,962). Conclusions: The addition of a third drug to a doublet chemotherapy regimen appeared more active in terms of response rate and PFS. However median OS resulted comparable. On this basis, a triplet regimen may represent an optimal choice, particularly when response and PFS are relevant treatment endpoints. Nevertheless the use of a sequential approach may also represent a reasonable strategy for patients unwilling or unable to undergo a more intensive treatment without compromising OS.
Collapse
Affiliation(s)
- Alessandro Bittoni
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| | - Mario Scartozzi
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| | - Mirco Pistelli
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| | - Eva Galizia
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| | - Michela Del Prete
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| | - Riccardo Giampieri
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| | - Luca Faloppi
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| | - Maristella Bianconi
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| | - Elena Maccaroni
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| | - Stefano Cascinu
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche , Ancona, Italy; Scuola di Specializzazione
| |
Collapse
|
15
|
Scartozzi M, Giampieri R, Mandolesi A, Maccaroni E, Del Prete M, Faloppi L, Bittoni A, Bianconi M, Galizia E, Silva RR, Giustini L, Zaniboni A, Labianca R, Bearzi I, Cascinu S. Correlation of activated AKT and MAPK expression in liver metastases with clinical outcome in colorectal cancer patients receiving irinotecan/cetuximab treatment. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.4_suppl.449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
449 Background: An aberrant activation of the EGFR downstream signaling pathway via MAP-kinase and Akt could be responsible for resistance to anti-EGFR treatment. We tested the interaction between phosphorylated Akt and MAPK in primary colorectal tumours and corresponding metastases and clinical outcome in terms of response rate (RR), progression free survival (PFS) and overall survival (OS) to identify a group of patients more likely to benefit from EGFR-targeted treatment among those harbouring a K-RAS wild type status. Methods: Seventy-two advanced K-RAS wild type colorectal cancer patients treated with irinotecan-cetuximab were analysed. Primary tumour were available in all cases, whereas paired tumour samples from metastatic sites were available in 37 patients. Phosphorylated Akt and MAPK were analyzed by immunohistochemistry. Results: Akt resulted overexpressed in 31 primary tumours (43%) and 23 metastases (62%), whereas MAPK was over-expressed in 32 primary tumours (44%) and 20 metastases (54%). Akt altered expression in primary tumours correlated with a statistically significant worse median PFS (2.4 months vs. 6.5 months, p= 0.0006) and OS (7.8 months vs. 26.7 months, p < 0.0001), without any significant correlation with RR. No significant correlation could be found between MAPK expression in primary tumours and RR, PFS or OS. In metastases Akt expression correlated with RR (9% vs, 58%, p= 0.004), PFS (2.3 months vs.9.2 months p < 0.0001) and OS (6.1 months vs.26.7 months p < 0.0001). Analogously MAPK expression in metastases correlated with RR (10% vs, 47%, p = 0.002), PFS (2.3 months vs.8.6 months p < 0.0001) and OS (7.8 months vs.26 months p = 0.0004). At multivariate analysis Akt and MAPK status in metastases was able to independently predict PFS. Akt status in metastases independently correlated with RR as well. Conclusions: We suggest that Akt and MAPK expression in metastases may have a relevant role in determining the activity of anti-EGFR treatment strategies. Our observations seem also to indicate that for some molecular determinants of resistance the biological profile in metastases is prominent.
Collapse
Affiliation(s)
- Mario Scartozzi
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Riccardo Giampieri
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Alessandra Mandolesi
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Elena Maccaroni
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Michela Del Prete
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Luca Faloppi
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Alessandro Bittoni
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Maristella Bianconi
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Eva Galizia
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Rosa Rita Silva
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Lucio Giustini
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Alberto Zaniboni
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Roberto Labianca
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Italo Bearzi
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| | - Stefano Cascinu
- Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Università Politecnica delle Marche, Anona, Italy; Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in
| |
Collapse
|
16
|
Scartozzi M, Loretelli C, Berardi R, Pierantoni C, Silva RR, Mari D, Giampieri R, Faloppi L, Pistelli M, Maccaroni E, Bittoni A, Del Prete M, Galizia E, Cascinu S. Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. Dig Liver Dis 2012; 44:74-9. [PMID: 21893437 DOI: 10.1016/j.dld.2011.08.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2011] [Revised: 07/30/2011] [Accepted: 08/04/2011] [Indexed: 12/11/2022]
Abstract
BACKGROUND Retrospective analyses suggested that a pharmacogenetic approach may allow a tailored selection of chemotherapy for metastatic colorectal cancer. AIM We conducted a phase II study of pharmacogenetic-selected first-line chemotherapy in elderly patients with advanced colorectal cancer, with the aim to improve efficacy and to reduce toxicity in this group of patients. METHODS 24 patients were enrolled in this study. Chemotherapy regimen was prospectively assigned based on TS, DPD, ERCC-1 and UGT1A1 genotyping results. Twelve patients (50%) were treated with modified FOLFIRI, 11 patients (46%) with modified FOLFOX6 and 1 (4%) with De Gramont regimen. RESULTS A partial remission was obtained in 4 cases (17%), stable disease in 8 cases (33%) and progressive disease in 12 cases (50%). Grade 3-4 neutropenia was observed in 7 patients (29%) and diarrhoea in 3 cases (12%). The trial was then interrupted according to study design requiring 13 partial remissions out of the first 24 patients enrolled as the necessary response rate level in order to continue. CONCLUSION Prospective selection of chemotherapy based on TS, DPD, ERCC-1 and UGT1A1 expression in elderly advanced colorectal cancer patients failed to confirm previous results. A more accurate validation of retrospective findings is warranted before these molecular markers can be used for treatment selection in the clinical practice.
Collapse
Affiliation(s)
- Mario Scartozzi
- Clinica di Oncologia, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F, Falcone A, Bearzi I, Cascinu S. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann Oncol 2011; 23:1706-12. [PMID: 22112971 DOI: 10.1093/annonc/mdr558] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND A large proportion of colorectal cancer patients does not benefit from the use of anti-epidermal growth factor receptor (EGFR) treatment although in the absence of a mutation of the K-RAS gene. Preliminary observations suggested that HER-3, insulin-like growth factor-1 (IGF-1), nuclear factor-kB (NF-kB) and EGFR gene copy number (GCN) might identify patients not likely to benefit from anti-EGFR therapy. We tested the interaction between HER-3, IGF-1, NF-kB, EGFR GCN and K-RAS mutational analysis to verify the relative ability of these variables to identify a subgroup of patients more likely to benefit from EGFR-targeted treatment among those harbouring a K-RAS wild-type status. PATIENTS AND METHODS We retrospectively collected tumours from 168 patients with metastatic colorectal cancer treated with irinotecan-cetuximab. K-RAS was assessed with direct sequencing, EGFR amplification was assessed by chromogenic in situ hybridisation (CISH) and HER-3, IGF-1 and NF-kB were assessed by immunohistochemistry. RESULTS In patients with K-RAS wild-type tumours, the following molecular factors resulted independently associated with response rate: HER-3 [odds ratio (OR)=4.6, 95% confidence interval (CI) 1.8-13.6, P=0.02], IGF-1 (OR=4.2, 95% CI 2-10.2, P=0.003) and EGFR GCN (OR=4.1, 95% CI 1.9-26.2, P=0.04). These factors also independently correlated with overall survival as follows: HER-3 [hazard ratio (HR)=0.4, 95% CI 0.28-0.85, P=0.008], IGF-1 (HR=0.47, 95% CI 0.24-0.76, P<0.0001) and EGFR GCN (HR=0.59, 95% CI 0.22-0.89, P=0.04). DISCUSSION We believe that our data may help further composing the molecular mosaic of EGFR-resistant tumours. The role of HER-3, IGF-1 and CISH EGFR GCN should be prospectively validated in clinical trials investigating anti-EGFR treatment strategies in colorectal cancer patients.
Collapse
Affiliation(s)
- M Scartozzi
- Department of Medical Oncology, United Hospitals, and Postgraduate School in Medical Oncology, University of Ancona, Ancona, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Scartozzi M, Loretelli C, Mandolesi A, Galizia E, Bittoni A, Faloppi L, Giampieri R, Pistelli M, Bearzi I, Cascinu S. PP 23 The role of vascular endothelial growth factor (VEGF) and VEGF-receptors genotyping in guiding the metastatic process in radically resected gastric cancer patients. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72701-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Pistelli M, Scartozzi M, Bittoni A, Galizia E, Berardi R, Cascinu S. Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. Tumori 2011. [PMID: 21789002 DOI: 10.1700/912.10021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS AND BACKGROUND Soon after the approval of irinotecan for second-line therapy of advanced gastric cancer, the FOLFIRI regimen represented a possible treatment choice in clinical practice. However, there was still scarce data on the efficacy of irinotecan in this setting. We retrospectively evaluated the efficacy of FOLFIRI as second-line treatment in advanced gastric cancer patients progressing after platinum-based chemotherapy. METHODS Patients with metastatic gastric cancer progressing after platinum-based chemotherapy who received FOLFIRI as second-line chemotherapy were included in our analysis. RESULTS Thirty patients were consecutively treated (20 males and 10 females). Median age was 62 years (range, 36-78). All patients had metastatic disease. In 17 cases (56.6%), peritoneal tumor diffusion was present. Six patients (20%) had previously received 5-fluorouracil-based adjuvant chemotherapy. The median number of cycles administered was 4 (range, 1-12). Partial remission was obtained in 1 case (3%) and stable disease in 8 patients (27%). Median progression-free survival and overall survival were 2.7 months and 5.5 months, respectively. The most common toxicities (grade 2-3) observed were neutropenia (13.3%), diarrhea (10%) and vomiting (30%). Ten patients (10%) received 3 or less courses of chemotherapy. In these cases, treatment was stopped before scheduled for accelerated worsening of clinical conditions. CONCLUSIONS FOLFIRI resulted scarcely active in metastatic gastric cancer patients pre-treated with platinum-based chemotherapy. In this setting, the real benefit of a second-line chemotherapy with the FOLFIRI regimen should be carefully re-considered, especially according to the clinical condition of the patient and possible treatment-related side effects.
Collapse
Affiliation(s)
- Mirco Pistelli
- Scuola di Specializzazione in Oncologia, Universitá Politecnica delle Marche, Ancona, Italy
| | | | | | | | | | | |
Collapse
|
20
|
Giampieri R, Scartozzi M, Loretelli C, Galizia E, Pistelli M, Bittoni A, Del Prete M, Mandolesi A, Siquini W, Berardi R, Trana C, Marmorale C, Fianchini A, Bearzi I, Cascinu S. Tumor angiogenesis as predictive factor for site of relapse in patients with gastric cancer: Biological and clinical implications. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Pistelli M, Scartozzi M, Bittoni A, Galizia E, Berardi R, Cascinu S. Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: Lessons from clinical practice. Tumori 2011; 97:275-9. [DOI: 10.1177/030089161109700303] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and background Soon after the approval of irinotecan for second-line therapy of advanced gastric cancer, the FOLFIRI regimen represented a possible treatment choice in clinical practice. However, there was still scarce data on the efficacy of irinotecan in this setting. We retrospectively evaluated the efficacy of FOLFIRI as second-line treatment in advanced gastric cancer patients progressing after platinum-based chemotherapy. Methods Patients with metastatic gastric cancer progressing after platinum-based chemotherapy who received FOLFIRI as second-line chemotherapy were included in our analysis. Results Thirty patients were consecutively treated (20 males and 10 females). Median age was 62 years (range, 36–78). All patients had metastatic disease. In 17 cases (56.6%), peritoneal tumor diffusion was present. Six patients (20%) had previously received 5-fluorouracil-based adjuvant chemotherapy. The median number of cycles administered was 4 (range, 1–12). Partial remission was obtained in 1 case (3%) and stable disease in 8 patients (27%). Median progression-free survival and overall survival were 2.7 months and 5.5 months, respectively. The most common toxicities (grade 2–3) observed were neutropenia (13.3%), diarrhea (10%) and vomiting (30%). Ten patients (10%) received 3 or less courses of chemotherapy. In these cases, treatment was stopped before scheduled for accelerated worsening of clinical conditions. Conclusions FOLFIRI resulted scarcely active in metastatic gastric cancer patients pre-treated with platinum-based chemotherapy. In this setting, the real benefit of a second-line chemotherapy with the FOLFIRI regimen should be carefully re-considered, especially according to the clinical condition of the patient and possible treatment-related side effects.
Collapse
Affiliation(s)
- Mirco Pistelli
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona
| | - Mario Scartozzi
- Clinica di Oncologia Medica, AO Ospedali Riuniti-Ancona, Università Politecnica delle Marche, Ancona
| | - Alessandro Bittoni
- Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona
| | - Eva Galizia
- Oncologia Medica, Ospedale “Profili”, Fabriano, Italy
| | - Rossana Berardi
- Clinica di Oncologia Medica, AO Ospedali Riuniti-Ancona, Università Politecnica delle Marche, Ancona
| | - Stefano Cascinu
- Clinica di Oncologia Medica, AO Ospedali Riuniti-Ancona, Università Politecnica delle Marche, Ancona
| |
Collapse
|
22
|
Scartozzi M, Siquini W, Galizia E, Stortoni P, Marmorale C, Berardi R, Fianchini A, Cascinu S. The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. Dig Liver Dis 2011; 43:194-8. [PMID: 20728416 DOI: 10.1016/j.dld.2010.07.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2010] [Revised: 06/23/2010] [Accepted: 07/17/2010] [Indexed: 12/11/2022]
Abstract
BACKGROUND The benefit of preoperative chemotherapy in patients with initially resectable liver metastases from colorectal cancer is still a matter of debate. AIMS We aim to evaluate the role of neoadjuvant chemotherapy on the outcome of patients with colorectal cancer metachronous liver metastases undergoing potentially curative liver resection. METHODS One-hundred four patients were available for analysis. Tested variables included age, sex, primary tumour TNM stage, location and grading, the number of liver metastases, monolobar or bilobar location, interval time between liver metastases diagnosis and liver resection, Fong Clinical Risk Score (CRS). Neoadjuvant chemotherapy was administered according to the FOLFOX4 regimen. RESULTS Forty-four patients underwent liver resection without receiving neoadjuvant chemotherapy (group A); 60 patients received neoadjuvant chemotherapy (group B). At univariate analysis, only the time of liver resection seemed to affect overall survival: patients in group A showed a median survival time significantly superior to that of patients in group B (48 vs. 31 months; p=0.0358). CONCLUSIONS Our findings suggest that, when feasible, resection of liver metastases should be considered as an initial approach in this setting. Further studies are needed to better delineate innovative therapeutic strategies that may lead to an improved outcome for colorectal cancer patients with surgically resectable liver metastases.
Collapse
Affiliation(s)
- Mario Scartozzi
- Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, via Conca, 60020 Ancona, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Scartozzi M, Mandolesi A, Giampieri R, Zaniboni A, Galizia E, Giustini L, Silva RR, Berardi R, Bearzi I, Cascinu S. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.404] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
404 Background: Preclinical data suggested that in presence of HER3 altered activation colorectal cancer cells may escape anti-EGFR mediated cell death. HER3 overexpression may then represent a key factor for resistance to anti-EGFR antibodies in colorectal cancer. The aim of our analysis was to investigate a possible correlation between HER3 expression and clinical outcome in KRAS wild-type advanced colorectal cancer receiving cetuximab and irinotecan. Methods: We retrospectively analyzed immunoreactivity for HER3 in KRAS wild-type advanced colorectal cancer patients receiving irinotecan-cetuximab. Results: Eighty-four advanced KRAS wild- type colorectal cancer patients were available for HER3 analysis. Forty patients (48%) showed HER3 negative colorectal tumor, whereas the remaining 44 cases (52%) were deemed HER3 positive. In HER3 negative and HER3 positive tumors we observed a partial response in 17 (42%) and 8 (18%) patients respectively (p = 0.04). Progressive disease was obtained in 11 (35%) and 26 (53%) patients with respectively HER3 negative and positive tumor (p = 0.007). No differences were observed for stable disease. Median PFS was 6.3 months in patients showing HER3 negative tumors and 2.8 months for those who had HER3 overexpressing tumors (p < 0.0001). Median overall survival was 13.6 months in patients showing HER3 negative tumors and 10.5 months for those who had HER3-expressing tumors (p = 0.01). Conclusions: HER3 proved to be a predictive factor for clinical outcome in KRAS wild-type colorectal cancer patients treated with cetuximab. Combined HER3 and KRAS analysis may represent an effective strategy for a better selection of responding colorectal tumors. Furthermore besides identifying colorectal cancer patients refractory to EGFR directed treatment, HER3 overexpression may also represent a potential biological indicator for the development of a new class of antineoplastic agents in this setting. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Scartozzi
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| | - A. Mandolesi
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| | - R. Giampieri
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| | - A. Zaniboni
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| | - E. Galizia
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| | - L. Giustini
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| | - R. R. Silva
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| | - R. Berardi
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| | - I. Bearzi
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| | - S. Cascinu
- Clinica di Oncologia Medica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Anatomia Patologica, A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; A. O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Oncologia Medica, Ospedale Profili, Fabriano, Italy; Ospedale Murri, Fermo, Italy; Ospedale E Profili, Fabriano, Italy
| |
Collapse
|
24
|
Scartozzi M, Mandolesi A, Giampieri R, Bittoni A, Pierantoni C, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biscotti T, Biagetti S, Bearzi I, Cascinu S. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 2011; 16:53-60. [PMID: 21212430 DOI: 10.1634/theoncologist.2010-0119] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Preclinical data suggested that, in the presence of human epidermal growth factor receptor (HER)-3-altered activation, colorectal cancer cells may escape anti-epidermal growth factor receptor (EGFR)-mediated cell death. HER-3 overexpression may then represent a key factor for resistance to anti-EGFR antibodies in colorectal cancer. The aim of our analysis was to investigate a possible correlation between HER-3 expression and clinical outcome in wild-type K-RAS advanced colorectal cancer patients receiving cetuximab and irinotecan. We retrospectively analyzed immunoreactivity for HER-3 in wild-type K-RAS advanced colorectal cancer patients receiving irinotecan and cetuximab. Eighty-four advanced wild-type K-RAS colorectal cancer patients were available for HER-3 analysis. Forty patients (48%) had a HER-3(-) colorectal tumor, whereas the remaining 44 cases (52%) were deemed HER-3(+). In patients with HER-3(-) and HER-3(+) tumors, we observed a partial response in 17 (42%) and eight (18%) patients respectively; progressive disease occurred in 11 (35%) and 26 (53%) patients with HER-3(-) and HER-3(+) tumors, respectively (p = .003). The median progression-free survival time was 6.3 months in patients with HER-3(-) tumors and 2.8 months for those who had HER-3-overexpressing tumors (p < .0001). The median overall survival time was 13.6 months in patients showing HER-3(-) tumors and 10.5 months for those who had HER-3-expressing tumors (p = .01). HER-3 proved to be a predictive factor for clinical outcome in wild-type K-RAS colorectal cancer patients treated with cetuximab. Combined HER-3 and K-RAS analysis may represent an effective strategy for better selection of responding colorectal cancer patients.
Collapse
Affiliation(s)
- Mario Scartozzi
- Clinica di Oncologia Medica, AO Ospedali Riuniti, Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Scartozzi M, Loretelli C, Bearzi I, Mandolesi A, Galizia E, Onofri A, Pistelli M, Bittoni A, Berardi R, Cascinu S. Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. Ann Oncol 2010; 22:897-902. [PMID: 20926544 DOI: 10.1093/annonc/mdq542] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Preclinical studies suggested that integrins are relevant for gastric cancer diffusion. We investigated integrins polymorphisms role in determining peritoneal carcinosis or hematogenous metastases in radically resected gastric cancer. PATIENTS AND METHODS Integrins genotyping was carried out on pT3 radically resected gastric tumors recurring with either peritoneal-only carcinosis or hematogenous metastases. RESULTS The following factors resulted independently associated with peritoneal carcinosis or hematogenous metastases: the A genotype of rs2269772 (ITGA3) [odds ratio (OR) for peritoneal carcinosis: 22.2, 95% confidence interval 1.2-40, P=0.03], the G genotype of rs2269772 (ITGA3) (OR for hematogenous metastases: 5.5, 95% confidence interval 2.2-14.15, P=0.0003), the C genotype of rs11902171 (ITGV) (OR for peritoneal carcinosis: 6.8, 95% confidence interval 1.3-33.4, P=0.01), the G genotype of rs11902171 (ITGV) (OR for hematogenous metastases: 2.5, 95% confidence interval 1.1-5.7, P = 0.02), diffuse histology (OR for peritoneal carcinosis: 4.7, 95% confidence interval 1.9-11.3, P=0.0005) and intestinal histology (OR for hematogenous metastases: 4.2, 95% confidence interval 1.9-9.9, P=0.0008). CONCLUSIONS Tumor histology represents a crucial issue conditioning tumoral behavior; genotyping of rs2269772 (ITGA3) and rs11902171 (ITGV) may be a further asset in the definition of high-risk patients for peritoneal carcinosis among those relapsing after curative resection. The selection tool deriving from this analysis may allow an optimal use of innovative treatment strategies.
Collapse
Affiliation(s)
| | | | - I Bearzi
- Department of Pathology, United Hospitals, Polytechnic Marche University, Ancona
| | - A Mandolesi
- Department of Pathology, United Hospitals, Polytechnic Marche University, Ancona
| | - E Galizia
- Department of Medical Oncology, Profili Hospital, Fabriano
| | - A Onofri
- Postgraduate School in Medical Oncology, United Hospitals, Polytechnic Marche University, Ancona, Italy
| | - M Pistelli
- Postgraduate School in Medical Oncology, United Hospitals, Polytechnic Marche University, Ancona, Italy
| | - A Bittoni
- Postgraduate School in Medical Oncology, United Hospitals, Polytechnic Marche University, Ancona, Italy
| | | | | |
Collapse
|
26
|
Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biagetti S, Menzo S, Falcone A, Bearzi I, Cascinu S. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 2010; 127:1941-7. [PMID: 20099280 DOI: 10.1002/ijc.25193] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Seventy to 40% of K-RAS wild type colorectal tumors does not seem to benefit from treatment with antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies. Recent data suggested that in presence of IGF-1 system, altered activation colorectal cancer cells may escape anti-EGFR mediated cell death. The interaction between IGF-1 expression and K-RAS mutational analysis was tested to verify the ability of IGF-1 to identify a subgroup of patients more likely to benefit from EGFR-targeted antibodies treatment. IGF-1 expression and K-RAS mutational status was assessed in advanced colorectal cancer patients receiving irinotecan/cetuximab. One hundred twelve patients were analyzed. IGF-1 was negative in 30 patients (27%) and overexpressed in the remaining 82 cases (73%). In IGF-1 negative and IGF-1 positive tumors, we observed progressive disease in 9 (30%) and 55 (67%) patients, respectively (p = 0.001). Median progression-free survival was 7.5 mo in patients showing IGF-1 negative tumors and 3 mo for IGF-1 expressing tumors (p = 0.002). Among K-RAS wild type patients, IGF-1 negative and positive tumors showed a partial response to cetuximab-irinotecan in 13 (65%) and 11 (22%) cases, respectively (p = 0.002). Median progression-free survival in IGF-1 negative tumors was 10 mo and 3.2 mo in IGF-1 positive colorectal cancers (p = 0.02). IGF-1 proved to be a possible predictive factor for resistance to anti-EGFR monoclonal antibodies in K-RAS wild type colorectal cancer. Combined IGF-1 and K-RAS analysis may represent an effective strategy for a better selection of responding colorectal cancer patients.
Collapse
Affiliation(s)
- Mario Scartozzi
- Department of Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Scartozzi M, Pistelli M, Bittoni A, Giampieri R, Galizia E, Berardi R, Faloppi L, Del Prete M, Cascinu S. Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy. Curr Oncol Rep 2010; 12:175-85. [PMID: 20425077 DOI: 10.1007/s11912-010-0101-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Although recent advances have been made, surgery still remains the mainstay of any curative treatment for gastric cancer patients, with radical gastrectomy representing the procedure of choice. However, patients with locally advanced disease show high rates of locoregional or distant recurrence even after potentially curative resections. According to global results presented in the setting of locally advanced resectable gastric carcinoma, perioperative chemotherapy may be considered a valuable option. On the other hand, clinical trials for advanced gastric cancer seem to suggest that a limit in efficacy has been reached for standard chemotherapy. Interesting data are expected from the development of targeted agents that, similarly to other cancer sites, showed appealing results in gastric cancer as well. Along with new effective therapeutic opportunities, better clinical and molecularly driven patient selection will represent the cornerstone of the global care for these patients.
Collapse
Affiliation(s)
- Mario Scartozzi
- Clinica di Oncologia Medica, AO Ospedali Riuniti, Università Politecnica delle Marche, via conca, 71, Ancona, 60020, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Scartozzi M, Loretelli C, Bearzi I, Mandolesi A, Galizia E, Pistelli M, Bittoni A, Berardi R, Giorgi F, Cascinu S. Correlation of tumor integrins and peritoneal carcinosis capability of gastric cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Galizia E, Giorgetti G, Piccinini G, Santinelli A, Loretelli C, Bianchi F, Gagliardini D, Carbonari G, Pisa E, Belvederesi L, Bracci R, Ferretti C, Corradini F, Cellerino R. BRCA1 expression in triple negative sporadic breast cancers. Anal Quant Cytol Histol 2010; 32:24-29. [PMID: 20701084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
OBJECTIVE To study how to identify patients with "triple negative" sporadic breast cancers (BCs) having BRCA1 silenced or down-regulated due to epigenetic BRCA1 inactivation. STUDY DESIGN We selected, from our database, patients diagnosed with BC between 1995 and 2001 with tumors exhibiting the "triple negative" phenotype. "Triple positive" tumors were used as controls. BRCA1 protein expression was determined by immunohistochemistry. Methylation specific polymerase chain reaction (PCR) and bisulfite sequencing on genomic DNA were used to assess BRCA1 promoter methylation. BRCA1 m-RNA expression analysis was conducted by real-time PCR. RESULTS Forty-four triple negative and 68 controls (triple positive) were eligible for our analysis. BRCA1 promoter methylation was present in 31.8% of triple negative and in 20.6% of triple positive cases. BRCA1 was inactivated (absent BRCA1 m-RNA expression and lack of BRCA1 protein) in 21.4% of tumors with BRCA1 promoter methylation, as compared with 6% of non-methylated ones (p = 0.0453). CONCLUSION BRCA1 inactivation due to promoter methylation could play an important role in some sporadic BC cases. Patients with this signature could represent the basis for prospective studies aiming to compare clinical response to different drugs.
Collapse
MESH Headings
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/secondary
- DNA Methylation
- Down-Regulation
- Female
- Gene Expression Regulation, Neoplastic
- Gene Silencing
- Humans
- Neoplasms, Hormone-Dependent/metabolism
- RNA, Messenger/metabolism
- Receptor, ErbB-2/metabolism
- Receptors, Estrogen/metabolism
- Receptors, Progesterone/metabolism
- Retrospective Studies
- Survival Rate
- Ubiquitin-Protein Ligases/genetics
- Ubiquitin-Protein Ligases/metabolism
Collapse
Affiliation(s)
- Eva Galizia
- Regional Center of Genetic Oncology, Department of Anatomic and Histologic Pathology and Clinic of Medical Oncology, Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Scartozzi M, Bearzi I, Mandolesi A, Galizia E, Pierantoni C, Loupakis F, Berardi R, Zaniboni A, Quadri A, Zorzi F, Biagetti S, Loretelli C, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S. Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. Anal Quant Cytol Histol 2009; 31:417-423. [PMID: 20698358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
OBJECTIVE To clarify the role of epidermal growth factor receptor (EGFR) promoter methylation in primary colorectal cancers and corresponding metastases and its relationship to EGFR expression. STUDY DESIGN Formalin-fixed tumor samples (primary site and metastasis)from colorectal cancer patients were analyzed for EGFR promoter methylation and EGFR immunohistochemistry expression. RESULTS Among the 63 assessable patients, 25 cases (39.7%) showed EGFR promoter methylation. Forty-two primary colorectal tumors and corresponding metastases were available for paired analysis of EGFR methylation status. EGFR methylation status of the primary tumor was in accordance with that of metastasis in 29 patients (69%). In contrast, 7 patients (50%) with EGFR promoter methylation in the primary tumor showed unmethylated EGFR in metastasis, and 6 metastases (46%) showed EGFR promoter hypermethylation derived from unmethylated EGFR primary tumors. Lack of EGFR protein expression was observed in 8 EGFR promoter methylated primary tumors (44%) and in 7 EGFR promoter methylated metastatic sites (44%). CONCLUSION EGFR promoter hypermethylation does not seem to represent a rare event in colorectal cancer and may be present differently in different tumor sites. These findings may be relevant to further studies investigating the role of EGFR in colorectal cancer patients.
Collapse
Affiliation(s)
- Mario Scartozzi
- Clinic of Medical Oncology, Azienda Ospedaliera Ospedali Riuniti-Università Politecnica delle Marche, Ancona Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009; 9:303. [PMID: 19712476 PMCID: PMC3087339 DOI: 10.1186/1471-2407-9-303] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2009] [Accepted: 08/27/2009] [Indexed: 12/02/2022] Open
Abstract
Background K-RAS wild type colorectal tumors show an improved response rate to anti-EGFR monoclonal antibodies. Nevertheless 70% to 40% of these patients still does not seem to benefit from this therapeutic approach. FISH EGFR GCN has been previously demonstrated to correlate with clinical outcome of colorectal cancer treated with anti-EGFR monoclonal antibodies. CISH also seemed able to provide accurate EGFR GCN information with the advantage of a simpler and reproducible technique involving immunohistochemistry and light microscopy. Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab. Methods Patients with advanced K-RAS wild-type, colorectal cancer receiving irinotecan-cetuximab after failure of irinotecan-based chemotherapy were eligible. A cut-off value for EGFR GCN of 2.6 and 2.12 for FISH and CISH respectively was derived from ROC curve analysis. Results Forty-four patients were available for analysis. We observed a partial remission in 9 (60%) and 2 (9%) cases with a FISH EGFR GCN ≥ 2.6 and < 2.6 respectively (p = 0.002) and in 10 (36%) and 1 (6%) cases with a CISH EGFR GCN ≥ 2.12 and < 2.12 respectively (p = 0.03). Median TTP was 7.7 and 6.4 months in patients showing increased FISH and CISH EGFR GCN whereas it was 2.9 and 3.1 months in those with low FISH and CISH EGFR GCN (p = 0.04 and 0.02 respectively). Conclusion FISH and CISH EGFR GCN may both represent effective tools for a further patients selection in K-RAS wild-type colorectal cancer treated with cetuximab.
Collapse
Affiliation(s)
- Mario Scartozzi
- Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, Faloppi L, Cascinu S. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 2009; 35:451-62. [PMID: 19467788 DOI: 10.1016/j.ctrv.2009.04.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2009] [Accepted: 04/15/2009] [Indexed: 02/07/2023]
Abstract
In the last few years therapeutic options for gastric cancer patients have slowly, but constantly expanded following the introduction of both new chemotherapy agents and innovative indications for treatment. Along with the medical therapy also our knowledge of the molecular mechanisms underlying this disease has progressively improved. However although the available treatment options have undoubtedly increased no clear definitive indications can be made for a standard chemotherapy regimen and we are still unable to accurately select the appropriate treatment for the appropriate patient. Many molecular determinants of response/toxicity to chemotherapy agents have been identified, but only few of them seem to possess the necessary potential for a subsequent application in the clinical practice. Some of these factors have also been indicated as a therapeutic target for a novel class of anti-cancer compounds. This systematic review will analyse available data about these factors with the aim to constitute a starting point for future research.
Collapse
Affiliation(s)
- Mario Scartozzi
- Clinica di Oncologia Medica, AO Ospedali Riuniti-Ancona, Università Politecnica delle Marche, Ancona, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Bianchi F, Galizia E, Catalani R, Belvederesi L, Ferretti C, Corradini F, Cellerino R. CAT25 is a mononucleotide marker to identify HNPCC patients. J Mol Diagn 2009; 11:248-52. [PMID: 19324995 PMCID: PMC2671342 DOI: 10.2353/jmoldx.2009.080155] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/27/2009] [Indexed: 12/31/2022] Open
Abstract
Mismatch repair mutations are the cause of generalized genomic instability and are particularly evident at microsatellite loci, which is known as microsatellite instability (MSI). MSI is present in 85% to 90% of colorectal cancers and occurs in hereditary non-polyposis colorectal cancer (HNPCC). The National Cancer Institute recommends the "Bethesda panel" for MSI screening. Recently, a novel T(25) mononucleotide marker was described, termed CAT25. This microsatellite marker displays a quasi-monomorphic pattern in normal tissues. The aim of our study was to evaluate the performance of CAT25 in HNPCC patients and to compare its reliability with the results of the Bethesda panel. We tested 55 tumor tissues from HNPCC patients using both the Bethesda panel and the CAT25 mononucleotide marker. One hundred healthy blood donors were used as controls. The CAT25 microsatellite was found to be altered in all 13 colorectal cancers classified as MSI-H using the standard Bethesda panel. Colorectal tumors that showed a stable Bethesda pattern did not show altered CAT25 repeats. Additionally, CAT25 showed a monomorphic allele pattern in all tissue samples. In our series, the concordance between the Bethesda panel and CAT25 in identifying colorectal cancers with high MSI reached 100%. Our results suggest that the CAT25 microsatellite represents a sensitive and specific marker for MSI and could be, at least, included in the panel of markers for the identification of HNPCC patients.
Collapse
Affiliation(s)
- Francesca Bianchi
- Centro Regionale di Genetica Oncologica, Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy.
| | | | | | | | | | | | | |
Collapse
|
34
|
Scartozzi M, Galizia E, Bianconi M, Berardi R, Cascinu S. Role of docetaxel in the treatment of advanced gastric carcinoma. CMI 2009. [DOI: 10.7175/cmi.v3i1.557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
With a median survival of 9-11 months, advanced gastric cancer represents one of the most aggressive neoplastic disease in western Countries. Radical surgery is considered the cornerstone for any curative procedure, however only a relatively small proportion of resected cases can be considered cured after surgery. In the last few years research data suggested that advanced gastric cancer can be classified into 2 distinct clinical categories: locally advanced (nonmetastatic, non resectable) and metastatic. While the therapeutic goal in the metastatic setting is palliation and survival improvement, in locally advanced cases one of the main goals of the treatment should be response with the aim to make resectable what was unresectable. The introduction of docetaxel for the treatment of advanced gastric cancer represented then a crucial step forward for the cure of this disease with an improvement in both survival and response rate. In this article we reviewed past and ongoing trials using docetaxel in gastric cancer with the aim to delineate a possible effective strategy for the treatment of this tumour
Collapse
|
35
|
Belvederesi L, Bianchi F, Galizia E, Loretelli C, Bracci R, Catalani R, Amati M, Cellerino R. MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system. Hum Mutat 2008; 29:E296-309. [PMID: 18781619 DOI: 10.1002/humu.20875] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is associated with germline mutations in one of several MisMatch Repair (MMR) genes. An increasing proportion (20-25%) of the reported MSH2 variants consists of single amino-acid substitution with uncertain disease-causing significance. The present study was undertaken to functionally characterize 3 MSH2 nontruncating variants: p.Gly162Arg (c.484G>C), p.Asp167His (c.499G>C) and p.Arg359Ser (c.1077A>T). Missense alterations, were assessed in a human system for expression/stability and for the ability to heterodimerize with MSH6 and correctly localize into the nucleus. Functional assays results were correlated with clinical and genetic features indicative of HNPCC as MicroSatellite-Instability (MSI), abnormalities of MMR gene expression in tumour tissue (IHC) and familial history. p.Gly162Arg and p.Arg359Ser variants showed a clearly decreased expression level of the MutSá complex and were associated with an abnormal subcellular localization pattern, which can be suggestive of an incorrect MSH2/MSH6 heterodimerization. Functional analysis results were supported by MSI and IHC data and by familial cancer history. The subcellular localization assay, performed in a human expression system, classifies as pathogenetic two MSH2 nontruncating alterations providing a useful tool in genetic testing programs.
Collapse
Affiliation(s)
- Laura Belvederesi
- Centro Regionale di Genetica Oncologica - Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2008; 20:227-30. [PMID: 18842611 DOI: 10.1093/annonc/mdn637] [Citation(s) in RCA: 253] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Arterial hypertension occurring during antiangiogenic therapy has been correlated with the biological inhibition of the vascular endothelial growth factor-related pathway and may represent a possible clinical marker for treatment efficacy. The aim of our study was to retrospectively assess if grades 2-3 hypertension were associated with response to bevacizumab, progression-free survival (PFS) and survival in metastatic colorectal cancer patients treated with first-line bevacizumab. PATIENTS AND METHODS Patients with histologically proven, metastatic colorectal cancer receiving bevacizumab as first-line therapy in combination with irinotecan and 5-fluorouracil were eligible for our analysis. RESULTS Thirty-nine metastatic colorectal cancer patients were eligible. Eight patients (20%) developed grades 2-3 hypertension. A partial remission was observed in six of eight cases with bevacizumab-related hypertension (75%) and in 10 of 31 (32%) patients with no hypertension (P = 0.04). Median PFS was 14.5 months for patients showing bevacizumab-related hypertension, while it was 3.1 months in those without hypertension (P = 0.04). Median overall survival was not reached in patients with hypertension while it was 15.1 months in the remaining cases (P = 0.11). CONCLUSIONS Our data indicate that bevacizumab-induced hypertension may represent an interesting prognostic factor for clinical outcome in advanced colorectal cancer patients receiving first-line bevacizumab.
Collapse
Affiliation(s)
- M Scartozzi
- Clinic of Medical Oncology, Polytechnic University of the Marche Region, Riuniti Hospital, Ancona, Italy.
| | | | | | | | | | | | | |
Collapse
|
37
|
Belvederesi L, Bianchi F, Galizia E, Catalani R, Bracci R, Loretelli C, Amati M, Cellerino R. Assessement of the pathogenic role of MSH2 missense variants in HNPCC syndrome. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Braconi C, Bracci R, Bearzi I, Bianchi F, Costagliola A, Catalani R, Mandolesi A, Ranaldi R, Galizia E, Cascinu S, Rossi G, Giustini L, Latini L, Valeri N, Cellerino R. KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann Oncol 2008; 19:706-10. [PMID: 18187489 DOI: 10.1093/annonc/mdm503] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The prognostic significance of KIT or platelet-derived growth factor receptor alpha (PDGFRalpha) mutations in gastrointestinal stromal tumors (GISTs) is still controversial. PATIENTS AND METHODS In all, 104 patients were diagnosed with GISTs by KIT immunoreactivity; tumor DNA was sequenced for the presence of mutations in KIT exons 9, 11, 13 and 17 and in PDGFRalpha exons 12 and 18. Disease-free survival (DFS) was analyzed in 85 radically resected patients. RESULTS KIT mutations occurred in exon 11 (69), in exon 9 (11) and in exon 17 (1). PDGFRalpha mutations were detected in exon 18 (10) and in exon 12 (3). Ten GISTs were wild type. Exon 11 mutations were as follows: deletions in 42 cases and point mutations in 20 cases and insertions and duplications, respectively, in 2 and 5 cases. A better trend in DFS was evident for duplicated and point-mutated exon 11 KIT GISTs. There was a significant association between PDGFRalpha mutations, gastric location and lower mitotic index. Moreover, PDGFRalpha-mutated GISTs seemed to have a better outcome. CONCLUSIONS Point mutations and duplications in KIT exon 11 are associated with a better clinical trend in DFS. PDGFRalpha-mutated GISTs are preferentially localized in the stomach and seem to have a favorable clinical behavior.
Collapse
Affiliation(s)
- C Braconi
- Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Bianchi F, Galizia E, Porfiri E, Belvederesi L, Catalani R, Loretelli C, Bracci R, Bearzi I, Turchi C, Viel A, Cellerino R. A missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-Italy. Fam Cancer 2007; 6:97-102. [PMID: 17165155 DOI: 10.1007/s10689-006-9110-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2006] [Accepted: 10/17/2006] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is an autosomal dominant inherited disease predisposing to the development of colorectal cancers and several other malignancies (endometrium, ovaries, stomach, small bowel, hepatobiliary and urinary tract). HNPCC is caused by germline mutations in any of the MisMatch Repair (MMR) genes. Mutations in MLH1 and MSH2 account for almost 90% of all identified ones. About 15% of mutations identified in MSH2 are missense ones. PATIENTS AND METHODS We studied one family, fulfilling Amsterdam II criteria, referred to our Center for genetic counselling. The proband, and some of her relatives, have been investigated for microsatellite instability (MSI), immunohistochemical MMR protein staining and by direct sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA). RESULTS All patients carried the same novel MSH2 germline missense mutation (R359S) in exon 7, which determines the substitution of an Arginine, which is a basic amino acid, with a polar Serine residue (R359S). The mutation was associated with lack of expression of MSH2 protein and high microsatellite instability in tumour tissues. The same mutation has been detected in one healthy relative. CONCLUSIONS The mutation here reported shows a high correlation with phenotype. The mutation is located in an evolutionary conserved domain. Taken together, our findings suggest evidence that the amino acid substitution can be interpreted as pathogenetic.
Collapse
Affiliation(s)
- Francesca Bianchi
- Istituto di Medicina Clinica e Biotecnologie Applicate-Oncologia Medica, Università Politecnica delle Marche, via Tronto, 60020 Ancona, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Giorgetti G, Galizia E, Bianchi F, Ferretti C, Corradini F, Belvederesi L, Piccinini G, Loretelli C, Santinelli A, Cellerino R. Genotype and phenotype in hereditary and sporadic breast cancers. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10538 Background: BRCA1 protein is involved in distinct DNA-repair processes. Germline mutations in BRCA1 gene confer cancer susceptibility. A frequent mechanism for epigenetic inactivation is hypermethylation of the CpG island in promoters of tumours suppressor genes. BRCA1 promoter hypermethylation has been found in a variable percentage of breast cancers (15–30%). BRCA1-associated breast cancers are usually high-grade, poorly differentiated and stain negative for HER2/neu, oestrogen and progesterone receptors (ER, PgR). Many studies have shown that hereditary BRCA1 and basal-like sporadic breast tumours have a similar phenotype and gene expression signature. Methods: By clinical criteria, 223 patients were selected and, for each patient, the probability to carry a BRCA1 mutation was calculated using the software BRCAPRO and Manchester Score System. All patients were studied by direct sequencing and MLPA of BRCA1 Open Reading Frames (ORFs). Thirty sporadic breast carcinomas, from women undergone surgery for primary invasive breast carcinoma between 1995 and 2001, were selected on the basis of negative staining for ER, PgR and HER2/neu (“BRCA-like”). In these patients, Methylation Specific-PCR and Bisulfite Sequencing on genomic DNA (obtained from sections of paraffin-embedded tissues and modified with sodium bisulfite) were used to assess the methylation pattern of BRCA1 promoter. BRCA1 immunohystochemical analysis (IHC) was performed in all patients. Results: We identified 17 patients with deleterious germline mutations in BRCA1. In “BRCA-like” patients, 13 methylated and 17 unmethylated cases were found by methylation analysis of BRCA1 promoter. The BRCA1 IHC was performed in all available samples ( table 1 ). Conclusions: Hypermethylation of BRCA1 promoter was found in 43% of “BRCA- like” patients. Expression of BRCA1 seems to correlate with hypermethylation of its promoter. Further studies are in progress to better understand the possible role of BRCA1 promoter hypermethylation in sporadic breast cancers. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Giorgetti
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| | - E. Galizia
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| | - F. Bianchi
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| | - C. Ferretti
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| | - F. Corradini
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| | - L. Belvederesi
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| | - G. Piccinini
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| | - C. Loretelli
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| | - A. Santinelli
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| | - R. Cellerino
- Ospedali Riuniti - Università Politecnica delle Ma, Ancona, Italy; Università Politecnica delle Marche, Ancona, Italy
| |
Collapse
|
41
|
Scartozzi M, Galizia E, Verdecchia L, Berardi R, Antognoli S, Chiorrini S, Cascinu S. Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother 2007; 8:797-808. [PMID: 17425475 DOI: 10.1517/14656566.8.6.797] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Chemotherapy is of crucial importance in advanced gastric cancer patients, in order to obtain palliation of symptoms and improve survival. The most extensively studied drugs as single agents are 5-fluorouracil, cisplatin, doxorubicin, epirubicin, mitomycin C and etoposide. Newer chemotherapeutic agents include the taxanes (docetaxel and paclitaxel), oral fluoropyrimidines (capecitabine and S-1), oxaliplatin and irinotecan. Randomised trials comparing monotherapy with combination regimens have consistently shown increased response rates in favour of combination regimens, whereas only marginally improved survival rates were usually found. Several combination therapies have been developed and have been examined in Phase III trials. However, in most cases, they have failed to demonstrate a survival advantage over the reference arm. There is no internationally accepted standard of care, and uncertainty remains regarding the choice of the optimal chemotherapy regimen. The objective of this article is to review the present literature available on major Phase II - III clinical trials, in which patients suffering from advanced gastric cancer were treated with cytotoxic chemotherapy.
Collapse
Affiliation(s)
- Mario Scartozzi
- Università Politecnica delle Marche, Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
| | | | | | | | | | | | | |
Collapse
|
42
|
Bianchi F, Galizia E, Bracci R, Belvederesi L, Catalani R, Loretelli C, Giorgetti G, Ferretti C, Bearzi I, Porfiri E, Cellerino R. Effectiveness of the CRCAPRO program in identifying patients suspected for HNPCC. Clin Genet 2007; 71:158-64. [PMID: 17250665 DOI: 10.1111/j.1399-0004.2007.00746.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Subjects affected by hereditary non-polyposis colorectal cancer exhibit a high susceptibility to colon and extracolonic tumours, due to MMR gene defects. Revised Bethesda criteria are used to select patients as candidates for genetic tests. Recently, the CRCAPRO model has been developed, based on family history of colorectal and endometrial cancers. Our study aims to evaluate the reliability of CRCAPRO in identifying mutation carriers. We used the CRCAPRO program to evaluate carrier probability risk in 99 patients fulfilling Amsterdam or Bethesda guidelines. MLH1 and MSH2 were studied by direct sequencing in all the 99 patients, and the study of microsatellite instability and of MMR proteins expression was performed. Nine MLH1 and nine MSH2 germline mutations were identified. Five out of the nine patients with MLH1 mutation showed a CRCAPRO risk evaluation of less than 20%. The same happened for four out of nine patients with MSH2 mutation. Of the 17 patients with an estimated risk of more than 80%, only four harboured a mutation, all in the MSH2 gene. The highest risk calculated by the CRCAPRO system in the nine carriers of a MLH1 mutation has been 31.7%. In our experience, the CRCAPRO program sensitivity and specificity appears to be low but needs to be further evaluated in larger samples.
Collapse
Affiliation(s)
- F Bianchi
- Centro Regionale di Genetica Oncologica, Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Scartozzi M, Galizia E, Verdecchia L, Berardi R, Graziano F, Catalano V, Giordani P, Mari D, Silva RR, Marmorale C, Zingaretti C, Cascinu S. Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer 2006; 95:445-9. [PMID: 16880789 PMCID: PMC2360670 DOI: 10.1038/sj.bjc.6603286] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The availability of different treatment options for radically resectable gastric cancer reopened the question of treatment selection and correct definition of high-risk categories. Lymphatic, blood vessel and perineural invasion (LBVI/PNI) seem to possess the necessary potential to provide useful information for the clinical management of this disease. Seven hundred and thirty-four patients with advanced gastric cancer who underwent curative gastrectomy were analysed according to the presence of LBVI/PNI. Patients were divided into two groups: group A for patients with LBVI/PNI (189 patients 26%) and group B for patients without LBVI/PNI (545 patients, 74%). The disease-free survival (DFS) for patients in group A was 32.1 months, whereas it was not reached for patients in group B (P=0.0001); the median overall survival was 45.5 months for patients in group A, whereas it was not reached for patients in group B (P=0.0001). At multivariate analysis, the presence of LBVI/PNI appeared an independent prognostic factor for DFS and OS. Our results were confirmed in subgroup analysis, separately considering stage I and early gastric cancer patients with and without LBVI/PNI. Taken together, our findings suggest the importance of LBVI/PNI in gastric cancer as it may provide additional information for identifying patients at high risk, who may be candidates for further medical treatment after or before surgery.
Collapse
Affiliation(s)
- M Scartozzi
- The Departments of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
| | - E Galizia
- Istituto di Medicina Clinica e Biotecnologie Applicate-Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy
| | - L Verdecchia
- The Departments of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
| | - R Berardi
- The Departments of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
| | - F Graziano
- Oncologia Medica, Ospedale di Urbino, Urbino, Italy
| | - V Catalano
- Oncologia Medica, Azienda Ospedaliera S Salvatore, Pesaro, Italy
| | - P Giordani
- Oncologia Medica, Azienda Ospedaliera S Salvatore, Pesaro, Italy
| | - D Mari
- Oncologia Medica, Ospedale di Fabriano, Fabriano, Italy
| | - R R Silva
- Oncologia Medica, Ospedale di Fabriano, Fabriano, Italy
| | - C Marmorale
- Clinica di Chirurgia Azienda Ospedaliera Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy
| | - C Zingaretti
- Chirurgia, Azienda Ospedaliera S Salvatore, Pesaro, Italy
| | - S Cascinu
- The Departments of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
- E-mail:
| |
Collapse
|
44
|
Belvederesi L, Bianchi F, Loretelli C, Gagliardini D, Galizia E, Bracci R, Rosati S, Bearzi I, Viel A, Cellerino R, Porfiri E. Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features. Eur J Hum Genet 2006; 14:853-9. [PMID: 16724012 DOI: 10.1038/sj.ejhg.5201628] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Assessing the pathogenicity of missense mutations of MLH1 and MSH2 is critical to counsel patients with suspected hereditary nonpolyposis colorectal cancer (HNPCC). Approximately 32% of all MLH1 mutations and 18% of MSH2 mutations are missense variants which often have an uncertain genetic significance. To assess the pathogenicity of four MLH1 missense mutations which were found in five patients with suspected HNPCC, P648S (CCC --> TCC), L559R (CTG --> CGG), K618A (AAG --> GCG), Y646C (TAT --> TGT), we studied their ability to disrupt MLH1 protein function and their relationship with all those clinical, genetic and pathological features which are typical of this syndrome. Our results indicated that the P648S and L559R mutations were probably pathogenic because they disrupted MLH1 protein interaction with its partner PMS2 in vitro and abolished MLH1 expression in HCT116 cells. In addition these variants were associated with features often found in HNPCC patients: in particular high microsatellite instability, occurrence of high grade tumours and, in one case, strong family history. The pathogenicity of the K618A and Y646C mutations was questionable as their correlation with features typical of HNPCC was low and the outcome of the functional analysis was ambiguous. These observations suggested that a clinically usable assessment of the pathogenicity of MLH missense variants can be achieved through the analysis of multiple mutation characteristics among which loss of protein function, occurrence of microsatellite instability and family history seemed to have a predominant role.
Collapse
Affiliation(s)
- Laura Belvederesi
- Oncologia Medica, Facolta' di Medicina e Chirurgia, Università Politecnica delle Marche, Ancona, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Berardi R, Grilli G, Romagnoli E, Saladino T, Freddari F, Tamburrano T, Galizia E, Carbonari G, Mariani C, Braconi C, Pierantoni C, Battelli N, Scartozzi M, Cascinu S. [Paraneoplastic syndromes: a review]. Clin Ter 2005; 156:281-8. [PMID: 16463565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Modern oncology often obtains good results against earlier neoplasms, whilst it's still in difficulties against the advanced ones. The knowledge of paraneoplastic syndromes is crucial both to cure patients and to do an earlier diagnosis. When we recognize a paraneoplastic syndrome that comes before the clinic beginning of a neoplasm, perhaps we save a life. This review discusses all the main paraneoplastic syndromes, focusing mainly on their clinical aspect and reminding the most commonly associated cancers.
Collapse
Affiliation(s)
- R Berardi
- Clinica di Oncologia Medica, Azienda Ospedaliero, Università Politecnica delle Marche, Ancona, Italia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Belvederesi L, Bianchi F, Loretelli C, Gagliardini D, Rosati S, Catalani R, Galizia E, Bracci R, Porfiri E, Cellerino R. Interaction analysis of hMLH1 missense variants in patients selected for HNPCC syndrome. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Belvederesi
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| | - F. Bianchi
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| | - C. Loretelli
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| | - D. Gagliardini
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| | - S. Rosati
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| | - R. Catalani
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| | - E. Galizia
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| | - R. Bracci
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| | - E. Porfiri
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| | - R. Cellerino
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuni, Ancona, Italy; CR-UK Institute for Cancer Studies, Birmingham, United Kingdom
| |
Collapse
|
47
|
Bianchi F, Bracci R, Rosati S, Galizia E, Belvederesi L, Loretelli C, Giorgetti G, Giorgi F, Cellerino R. CRCAPRO: A statistical model to evalute the risk of MMR mutations. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Bianchi
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuniti, Ancona, Italy; Servizio Oncologia Medica, San Benedetto del Tronto, Italy
| | - R. Bracci
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuniti, Ancona, Italy; Servizio Oncologia Medica, San Benedetto del Tronto, Italy
| | - S. Rosati
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuniti, Ancona, Italy; Servizio Oncologia Medica, San Benedetto del Tronto, Italy
| | - E. Galizia
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuniti, Ancona, Italy; Servizio Oncologia Medica, San Benedetto del Tronto, Italy
| | - L. Belvederesi
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuniti, Ancona, Italy; Servizio Oncologia Medica, San Benedetto del Tronto, Italy
| | - C. Loretelli
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuniti, Ancona, Italy; Servizio Oncologia Medica, San Benedetto del Tronto, Italy
| | - G. Giorgetti
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuniti, Ancona, Italy; Servizio Oncologia Medica, San Benedetto del Tronto, Italy
| | - F. Giorgi
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuniti, Ancona, Italy; Servizio Oncologia Medica, San Benedetto del Tronto, Italy
| | - R. Cellerino
- Università Politecnica delle Marche, Ancona, Italy; Azienda Ospedali Riuniti, Ancona, Italy; Servizio Oncologia Medica, San Benedetto del Tronto, Italy
| |
Collapse
|
48
|
Scartozzi M, Galizia E, Graziano F, Catalano V, Berardi R, Baldelli AM, Testa E, Mari D, Silva RR, Cascinu S. Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. Br J Cancer 2005; 92:1051-4. [PMID: 15770210 PMCID: PMC2361942 DOI: 10.1038/sj.bjc.6602468] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The aim of our analysis was to assess retrospectively the effect on local relapse, overall survival (OS) and disease-free survival (DFS) of a limited or an extended lymphadenectomy in radically resected gastric cancer patients. This study was performed in order to identify a subgroup of patients possibly not benefiting from a therapeutic approach such as chemoradiation therapy. We divided our patients into two groups according to lymphadenectomy type: group A for limited (<25 resected lymph nodes) and group B for extended (>25 resected lymph nodes) lymph nodes resection. A total of 418 patients were analysed: tumour stage at diagnosis was pT2–3 pN1–3 M0 in 339 patients and pT3 N0 M0 in 79 patients. Median age at diagnosis was 68 years (range 30–92 years). A total of 306 patients (73.2%) were in group A and 112 (26.8%) in group B. The median survival time (OS) for patients in groups A and B was 58.8 and 84.8 months, respectively (P=0.0371); median DFS was 28.8 months in group A and 59.9 months in group B (P=0.0027). At multivariate analysis, extension within the gastric wall, nodal involvement and the number of resected lymph nodes appeared to affect both OS and DFS. An inadequate lymph nodes resection can affect survival and result in a higher incidence of local relapse, making the latter group of patients optimal candidates for adjuvant chemoradiation.
Collapse
Affiliation(s)
- M Scartozzi
- Department of Medical Oncology, Università Politecnica delle Marche-Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
| | - E Galizia
- Department of Medical Oncology, Università Politecnica delle Marche-Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
| | - F Graziano
- Department of Medical Oncology, Ospedale di Urbino, Italy
| | - V Catalano
- Department of Medical Oncology, Azienda Ospedaliera S Salvatore, Pesaro, Italy
| | - R Berardi
- Department of Medical Oncology, Università Politecnica delle Marche-Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
| | - A M Baldelli
- Department of Medical Oncology, Azienda Ospedaliera S Salvatore, Pesaro, Italy
| | - E Testa
- Department of Medical Oncology, Ospedale di Urbino, Italy
| | - D Mari
- Department of Medical Oncology, Ospedale di Fabriano, Italy
| | - R R Silva
- Department of Medical Oncology, Ospedale di Fabriano, Italy
| | - S Cascinu
- Department of Medical Oncology, Università Politecnica delle Marche-Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
- Clinica di Oncologia Medica, Università Politecnica delle Marche-Azienda Ospedaliera Umberto I, Via Conca, 60020 Ancona, Italy. E-mail:
| |
Collapse
|
49
|
Abstract
Gastric cancer is the second most common cause of cancer-related deaths worldwide. Surgery remains the mainstay of any curative treatment; however, those patients who are considered not amenable of curative resection generally receive chemotherapy, in order to obtain palliation of symptoms and improved survival. Many drugs have been tested in several combination regimens yielding higher response rates. In spite of the fact that chemotherapy has been extensively used in advanced gastrointestinal cancer, there are few studies that focus on its economic costs. The aim of this paper is to review the results of the main studies regarding the relationship between the cost of chemotherapy and its effectiveness in advanced gastric and gastrointestinal cancer patients.
Collapse
Affiliation(s)
- Eva Galizia
- Univeritaria Ospedali Riuniti Umberto I, Salesi, Lancisi di Ancona, Italy
| | | | | | | |
Collapse
|
50
|
Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 2004; 30:451-9. [PMID: 15245777 DOI: 10.1016/j.ctrv.2004.01.001] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Both the availability of multiple treatment modalities and novel therapeutic targets make the correct prognostic stratification and the identification of truly predictive factors an issue of major debate in gastric cancer. Along with "classic" prognostic factors such as those related to the diffusion of the tumour at diagnosis (i.e., depth of gastric wall infiltration, locoregional lymph nodes or distant metastases) or those concerning the pathologic characteristics of the tumour, other, innovative, factors should be considered if a better definition of the characteristics of the tumour is to be given. These biological factors are often derived from the genetic process, which is thought to represent a crucial step to gastric cancer (DNA copy number changes, microsatellite instability, thymidilate synthase, E-cadherin, beta-catenin, mucin antigen, p53, c-erb B-2, COX-2, matrix metalloproteinases, VEGFR and EGFR). Some of those putative prognostic indicators can also be considered predictive of response to therapy as they are a molecular target either to chemotherapeutics (i.e., thymidilate synthase that is targeted by 5FU) or to a new class of antineoplastic molecules (i.e., c-erb B-2 targeted by trastuzumab, COX-2 by NSAIDs, matrix metalloproteinases, EGFR and VEGFR by specific inhibitors).
Collapse
Affiliation(s)
- Mario Scartozzi
- Clinica di Oncologia Medica, Università Politecnica delle Marche-Azienda Ospedaliera Umberto I, Ancona, Italy
| | | | | | | | | | | |
Collapse
|